Background Trimetazidine, as an anti-ischemic and antioxidant agent, has been
demonstrated to have many cardioprotective effects. However, whether early administration …

Aim: To investigate the influence of trimetazidine, which is known to be an antioxidant and
modulator of metabolism, on cardiac function and the development of diabetic …

Diabetic cardiomyopathy (DCM) is characterized by cardiac hypertrophy, fibrosis, oxidative
stress and inflammation. Trimetazidine (TMZ), a potent metabolism modulator, has been …

Trimetazidine (TMZ) has been demonstrated to have protective effects against myocardial
ischemia/reperfusion (MI/R) injury. In the present study, we investigated the effects and the …

Trimetazidine, a piperazine derivative used as an anti-anginal agent, improves myocardial
glucose utilization through inhibition of fatty acid metabolism. The present study was …

Background Metabolic remodeling plays a vital role in the development of heart failure. The
trimetazidine can optimize fatty acid and glucose oxidation via inhibition of long-chain 3 …

Diabetic cardiomyopathy is a type of cardiac dysfunction resulting from diabetes,
independent of vascular or valvular pathology. It clinically manifests initially as asymptomatic …

Diabetes may affect myocardial fibrosis through oxidative stress. Trimetazidine (TMZ) is an
anti‑anginal agent. The present study aimed to determine the modulatory effect of TMZ on …

Diabetic cardiomyopathy (DCM) is an important cause of heart failure in diabetic patients.
The present study sought to explore the potential effects of dihydromyricetin (DHM) on DCM …

Energic deficiency of cardiomyocytes is a dominant cause of heart failure. An antianginal
agent, trimetazidine improves the myocardial energetic supply. We presumed that …